They reveal which vaccine is the most popular in Argentina, which generates the most rejection and why

Made nine months vaccination against Covid-19. On December 24, 2020, the first batch of 300,000 vaccines arrived and the official launch of the campaign took place five days later, at Posadas Hospital. After the time equivalent to that of a full term pregnancy, the baby it’s pronounced.

Much has been said about the national immunization plan, but little was known about the degree of satisfaction Argentines with what has been done by the national state and the provinces in the race against the coronavirus. A poll conducted last week across the country gives voice, for the first time, at vaccinated.

The work, carried out by the D’Alessio Irol design office for Bugle, including 734 over 18 years old. They answered questions online about the vaccination operation in general and the particular experience they have had, of the vaccine they received, how many doses they received and in which district they were registered.

The first data that emerge from the survey: the people consulted were, in general, more agree with the vaccine which made its luck with the vaccination operation. On average, the 78 percent of the people consulted answered in the affirmative in the first case, against only the 62 percent In a second.

By dividing the people interviewed by vaccine brand received, Sputnik V is the one with the worst consideration among the three most used of the country, with AstraZeneca and Sinopharm, despite the fact that Russian has greater efficiency. Among those who only received the first installment of Sputnik, the 71 percent He accepted and the 24 percent, unhappy.

Those who received the second component improved their assessment by a few points: the 74 percent expressed satisfaction, while 21 percent said the opposite. In other words, even with the two doses of Sputnik, the Argentines evaluated the drug from the Gamaleya Institute. Below average general considerations of the vaccinated.

The survey looked at the reasons for the disagreement: the first of these, with 29% of responses, was that “Sputnik is not internationally recognized, it does not allow travel abroad ”. It is striking to note that this argument prevailed over another more fundamental one: the delay in the second dose application took 12 percent of objections.

Others grounds for rejection They were: “I would have preferred Pfizer” (15%); “I preferred another vaccine” (14%); “I would have preferred to choose” (12%); and “It doesn’t give me confidence” (13%). A 5 percent disenchantment was overwhelmed by the argument that the vaccine they received “is one of the least effective”.

The consultation of the vaccinated coincided with the week when it was learned that the United States would impose, in November, the obligation to have both doses against the Covid to enter this country. And that the activated vaccines could possibly be those approved by the World Health Organization. On this list for now no figure the Sputnik V.

At the other end of the local rankings, the vaccine that brought in the most approvals was AstraZeneca. In this case, among those who received only the first dose, the degree of satisfaction was 91 percenti.e. 13 percentage points above the general level of compliance for all vaccines. Only the 8 percent He said he was not happy with the one in Oxford.

Another striking result of the survey is that those who received the second dose of AstraZeneca showed slightly less approval than those who received only the first puncture. Was the 88 percent, while the negative consideration has shifted from 8 to 11 percent. Although the reason for this slight variation has not been investigated, any “time expired” to receive the second dose could be a clue.

Sinopharm’s Chinese vaccine was smack in the middle of the odds: people he doesn’t like it so much like AstraZeneca, but considers it Above of Sputnik V. A result that we could a priori attribute more to the bureaucratic problems that complicate the Russian vaccine as strictly sanitary.

The 78 percent of those who received a single dose of Sinopharm were satisfied with the vaccine, compared to a 15 percent not. With the two doses received, however, satisfaction rose to 80% and negative opinions remained at the same level.

Finally, there were surprising responses on two other vaccines: Covishield, which although being the same vaccine as that of AstraZeneca (Indian version) has shown satisfaction rates. quite inferior to those of the first: 78% with the first dose and 76% with both.

Regarding the considerations on Moderna, the questions obviously focused on those who received it. to combination in the second dose – they did not interview minors with co-morbidities – and there again, satisfaction was lower than the general averages: 68% said they were satisfied and 28% were not.

To put this assessment in context, it must be taken into account that people vaccinated with Moderna had almost no choice but to accept it in a clinic. heterologous esquema due to the absence of the second component of the Russian, although the combination test verified that the performance of the American is superior.

The operator

Finally, the Argentinian examination of the vaccination operation was the subject of an investigation. The 62 percent said very satisfied or somewhat satisfied, while the 34 percent was dissatisfied or very dissatisfied. After this first national measure, the survey also detailed the limited reactions to the city and province of Buenos Aires.

In the City, the positive note was something above of the general average of the country, with the 66 percent, while the negative was 32 percent. In the provinces, the 58 percent placed the vaccination operation within the threshold of positive considerations and 38 percent said the opposite.

In closing, we asked people Who is responsible the result of the vaccination operation: from the national state, the provinces or shared. It was the porteños who awarded him a more weight for the central government, while in the rest of the provinces, it has instead turned to a mixed responsibility.

Until now, our country received 67,708,045 vaccines against Covid: 28,856,000 from Sinopharm; 17,363,945 Sputnik V (10,955,280 from component 1 and 6,408,665 from component 2); 16,966,900 from AstraZeneca (13,200,500 from the purchase contract; 580,000 from Covishield; 1,944,000 from Covax; and 1,242,400 donations from Spain).

In addition, 3,500,000 from Moderna arrived, donated by the United States; 600,000 from Cansino and 421,200 from Pfizer. The last two brands, due to the reduced number of batches that have arrived so far and the short time they have had in Argentina, they were not included in the poll.

Of the 67.7 million vaccines arrived, approximately 51 million, out of a total of 55.2 million distributed across the provinces. This shows that Argentina has a stock of nearly 17 million doses unused. At the same time, only the 47 percent of the population were able to complete their vaccination schedule.

PS

TOPICS APPEARING IN THIS NOTE